The significant increases in CXCL13, CD163, and CXCL13/CD163 immunoreactivity of astrocytoma tissues were found in the apparently aggressive GBM subgroups (CXCL13, p = 0.0002; CD163, p < 0.0001; CXCL13/CD163, p < 0.0001; Figures 2G–I). This evidence concerns the gene CXCL13 and astrocytoma (excluding glioblastoma).